公开(公告)号：EP3626266A1

公开(公告)日：2020-03-25

申请号：EP18801322.1

申请日：2018-05-15

申请人： Jiangsu Hengrui Medicine Co., Ltd. ,  Shanghai Hengrui Pharmaceutical Co., Ltd

发明人： YAN, Zhen ,  YANG, Jianjian ,  YAN, Xiaodan ,  WU, Shan ,  LIU, Xun

IPC分类号： A61K39/395 ,  A61P35/00

摘要： The present invention provides a PD-L1 antibody pharmaceutical composition and use thereof. In particular, the present invention provides a pharmaceutical composition comprising the PD-L1 antibody or an antigen-binding fragment thereof in a succinate buffer. In addition, the pharmaceutical composition may also contain a sugar and a nonionic surfactant.

公开(公告)号：EP3939998A1

公开(公告)日：2022-01-19

申请号：EP19888794.5

申请日：2019-11-29

申请人： Jiangsu Hengrui Medicine Co., Ltd. ,  Shanghai Hengrui Pharmaceutical Co., Ltd

发明人： YANG, Jianjian ,  LI, Hao ,  LIU, Xun ,  JIANG, Jiahua

IPC分类号： C07K16/28 ,  A61K39/395 ,  A61P35/00

摘要： The present invention provides a pharmaceutical composition comprising a CD40 antibody or an antigen-binding fragment thereof and an acetic acid-sodium acetate buffer solution, and a use thereof. The pharmaceutical composition may further contain sugar, a non-ionic surfactant, and other excipients. The pharmaceutical composition of the present invention shows good antibody stability.